Evidence map›Paper›PMID 32330461›Full record

ReviewChest2020

Prevention of Asthma: Targets for Intervention.

Michelle C Maciag, Wanda Phipatanakul

Open access · greenAbstract readReview
In one paragraph

Review in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. A qualitative evaluation of asthma patients' treatment adherence and psychosocial challenges in their daily lives: A phenomenological design.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. L-serine metabolic regulation and host respiratory homeostasis.Frontiers in cellular and infection microbiology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Probiotics in Children with Asthma.Children (Basel, Switzerland) · 2022
    Review
  19. Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease.International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michelle C MaciagDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Wanda PhipatanakulDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA. Electronic address: Wanda.phipatanakul@childrens.harvard.edu.
Harvard University · US

Funding

Controlling and preventing Asthma progression and Severity in Kids (CASK)U01AI126614 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2016 to 2023
$21.0M
MOLECULAR BASIS OF ALLERGIC AND IMMUNOLOGIC DISEASET32AI007512 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI Janet Chou, Peter A Nigrovic · 1996 to 2026
$13.1M
SICAS- Diversity SupplementU01AI110397 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2015 to 2020
$8.8M
Midcareer Investigator Award: Urban School Allergen Exposures and Childhood AsthmK24AI106822 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2013 to 2022
$1.9M
NIAID NIH HHS K24 AI106822NIAID NIH HHS T32 AI007512NIAID NIH HHS U01 AI110397NIAID NIH HHS U01 AI126614
6 · The paper itself

Abstract

Approximately 300 million people worldwide are estimated to be affected by asthma, and the number of patients affected is growing exponentially-with potential for an additional 100 million people affected by the condition by 2025. With this increasing burden of disease, there is high motivation to discover effective prevention strategies. Strategies aimed at stalling the atopic progression, modifying the microbiome, preventing respiratory viral infections, and reducing the impact of toxin/pollutant exposure through dietary supplements have had limited success in the prevention of asthma. This is likely because asthma is heterogenous and is influenced by different genetic and environmental factors. Genes underlie a predisposition to asthma and allergic sensitization, whereas exposure to allergens, respiratory infections, and pollution may modify asthma pathogenesis and the variation in severity seen among individuals. Future advances in asthma prevention may include a more personalized approach: genetic variations among susceptible individuals with distinct asthma phenotypes or different biomarkers of disease may help individualize prevention strategies and render them more . In this article, we summarize interventions that have been studied for the prevention of asthma and identify some of the clinical trials that are actively underway in asthma prevention.

Indexed as

AdolescentAnti-Allergic AgentsAnti-Inflammatory AgentsAsthmaBiological ProductsChildChild, PreschoolDesensitization, ImmunologicEnvironmental ExposureHumansImmunotherapyInfantRespiratory Tract InfectionsVitamin D DeficiencyAnti-Allergic AgentsAnti-Inflammatory AgentsBiological Productsasthmaimmunotherapyomalizumabpreventionvitamin D

Identifiers

PMID32330461
PMCPMC7478233
OpenAlexW3017579845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.